Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed a novel pharmacological Inhibitor CEP1430 synthetic molecule that is capable of inhibiting the growth and proliferation of the human pancreatic cancer tumor. This molecule can be administrated by the following methods: intravenous and intra-peritoneal.
http://ift.tt/1ysEXKY
http://ift.tt/1ysEXKY
No comments:
Post a Comment